Aveo Pharms Drug Patent Portfolio
Aveo Pharms owns 1 orange book drug protected by 3 US patents Given below is the list of Aveo Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11504365 | Use of tivozanib to treat subjects with refractory cancer | 05 Nov, 2039 | Active |
| US6821987 | Quinoline derivatives and quinazoline derivatives having azolyl group | 26 Apr, 2025 | Active |
| US7166722 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | 16 Nov, 2024 | Active |
Latest Legal Activities on Aveo Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aveo Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Interim Patent Term Extension Granted
Critical
| 18 Mar, 2024 | US6821987 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US6821987 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US7166722 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US7166722 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US6821987 |
|
Interim Patent Term Extension Granted
Critical
| 05 Oct, 2023 | US7166722 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 Aug, 2023 | US7166722 |
|
Email Notification
Critical
| 15 Aug, 2023 | US7166722 |
|
Electronic Review
Critical
| 15 Aug, 2023 | US7166722 |
|
Email Notification
Critical
| 14 Aug, 2023 | US6821987 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Aug, 2023 | US6821987 |
|
Electronic Review
Critical
| 14 Aug, 2023 | US6821987 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 25 Jan, 2023 | US11504365 |
|
Interim Patent Term Extension Granted
Critical
| 24 Jan, 2023 | US6821987 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 22 Nov, 2022 | US11504365 |
Aveo Pharms's Family Patents
Aveo Pharms drugs have patent protection in a total of 26 countries. It's US patent count contributes only to 14.5% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Aveo Pharms Drug List
Given below is the complete list of Aveo Pharms's drugs and the patents protecting them.
1. Fotivda
Fotivda is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11504365 | Use of tivozanib to treat subjects with refractory cancer |
05 Nov, 2039
(15 years from now)
| Active |
| US6821987 | Quinoline derivatives and quinazoline derivatives having azolyl group |
26 Apr, 2025
(6 months from now)
| Active |
| US7166722 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
16 Nov, 2024
(a month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fotivda's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List